Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Olema Pharmaceuticals ( (OLMA) ) just unveiled an announcement.
On November 18, 2025, Olema Pharmaceuticals announced a public offering of 10,000,000 shares of its common stock at $19.00 per share, expected to close on November 20, 2025. The offering aims to raise approximately $190 million, excluding underwriting discounts and commissions, with an option for underwriters to purchase an additional 1,500,000 shares. This move is part of Olema’s strategy to strengthen its financial position and support its ongoing operations in the competitive pharmaceutical market.
The most recent analyst rating on (OLMA) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Olema Pharmaceuticals stock, see the OLMA Stock Forecast page.
Spark’s Take on OLMA Stock
According to Spark, TipRanks’ AI Analyst, OLMA is a Neutral.
Olema Pharmaceuticals faces substantial financial challenges with zero revenue and increasing losses, necessitating external funding. The technical analysis indicates some recent positive momentum, but the stock remains speculative due to negative profitability. The strategic collaboration with Novartis offers a positive outlook, potentially enhancing market position and supporting long-term growth. These factors collectively result in a moderate overall stock score.
To see Spark’s full report on OLMA stock, click here.
More about Olema Pharmaceuticals
Olema Pharmaceuticals operates in the pharmaceutical industry, focusing on the development and commercialization of therapies for women’s cancers.
Average Trading Volume: 2,551,206
Technical Sentiment Signal: Buy
Current Market Cap: $585M
For detailed information about OLMA stock, go to TipRanks’ Stock Analysis page.